[go: up one dir, main page]

UA87822C2 - Naphthylene derivatives as cytochrome p450 inhibitors - Google Patents

Naphthylene derivatives as cytochrome p450 inhibitors

Info

Publication number
UA87822C2
UA87822C2 UAA200601312A UAA200601312A UA87822C2 UA 87822 C2 UA87822 C2 UA 87822C2 UA A200601312 A UAA200601312 A UA A200601312A UA A200601312 A UAA200601312 A UA A200601312A UA 87822 C2 UA87822 C2 UA 87822C2
Authority
UA
Ukraine
Prior art keywords
cytochrome
inhibitors
treatment
naphthylene
derivatives
Prior art date
Application number
UAA200601312A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Ванесса Смит
Энтони Найгро
Марк Малвихилл
Кара Сесарио
Патришия Энн Бек
Арлиндо Лукас Кастелано
Original Assignee
Оси Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оси Фармасьютикалз, Инк. filed Critical Оси Фармасьютикалз, Инк.
Publication of UA87822C2 publication Critical patent/UA87822C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Compounds of the formula (I); and pharmaceutically acceptable salts thereof, wherein n1, n2, n3, n4, G,Q, Z, R, R, R, R, R, R, and Rare defined herein, inhibit the cytochrome P450RAI enzyme and are useful for the treatment and/or prevention of various diseases and conditions which respond to treatment by retinoids and by naturally occurring retinoic acid.(I)
UAA200601312A 2003-07-10 2004-12-07 Naphthylene derivatives as cytochrome p450 inhibitors UA87822C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48638203P 2003-07-10 2003-07-10

Publications (1)

Publication Number Publication Date
UA87822C2 true UA87822C2 (en) 2009-08-25

Family

ID=34079229

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200601312A UA87822C2 (en) 2003-07-10 2004-12-07 Naphthylene derivatives as cytochrome p450 inhibitors

Country Status (15)

Country Link
EP (1) EP1654236A1 (en)
JP (1) JP4832295B2 (en)
KR (1) KR20060052799A (en)
CN (1) CN1819996B (en)
AU (1) AU2004257257B2 (en)
BR (1) BRPI0412424A (en)
CA (1) CA2532078A1 (en)
IL (1) IL172812A0 (en)
IS (1) IS8223A (en)
MX (1) MXPA06000401A (en)
NO (1) NO20060114L (en)
RU (1) RU2363696C2 (en)
SG (1) SG144941A1 (en)
UA (1) UA87822C2 (en)
WO (1) WO2005007631A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468391B2 (en) 2003-12-17 2008-12-23 Allergan, Inc. Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B
US7662844B2 (en) 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
US8513291B2 (en) 2010-06-01 2013-08-20 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
EA024197B1 (en) * 2010-11-13 2016-08-31 Иннокрин Фармасьютикалс, Инк. Metalloenzyme inhibitor compounds
CA2820718A1 (en) * 2010-12-13 2012-06-21 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN102586187A (en) * 2012-02-23 2012-07-18 深圳市中美康士生物科技有限公司 In vitro preservation method and culture medium for neutrophils
US20160038490A1 (en) * 2012-07-18 2016-02-11 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
EP3180335B1 (en) 2014-08-11 2021-05-05 Angion Biomedica Corporation Cytochrome p450 inhibitors and uses thereof
CN104523967B (en) * 2014-12-12 2017-08-01 扬子江药业集团北京海燕药业有限公司 A kind of Bai Ai capsules as CYP enzyme inhibitors application
US10287282B2 (en) 2014-12-31 2019-05-14 Angion Biomedica Corp. Methods and agents for treating disease
GB201602572D0 (en) * 2016-02-12 2016-03-30 Eriksson Leif And Strid Ake And Sirsjö Allan New compound and uses
WO2018065288A1 (en) 2016-10-07 2018-04-12 Bayer Cropscience Aktiengesellschaft 2-[2-phenyl-1-(sulfonyl-methyl)-vinyl]-imidazo-[4,5-b] pyridine derivatives and related compounds as pesticides in plant protection
UY37556A (en) 2017-01-10 2018-07-31 Bayer Ag HETEROCYCLIC DERIVATIVES AS PESTICIDES
CN110312718B (en) 2017-01-10 2023-02-28 拜耳公司 Heterocyclene derivatives as pest control agents
WO2024223797A1 (en) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections
CN116903531B (en) * 2023-07-21 2025-12-12 上海中医药大学 Inhibitors of cytochrome P450 enzyme 3A4, their preparation methods and applications

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291944A (en) * 1960-05-04
NL131915C (en) * 1966-07-27
DE3508903A1 (en) * 1985-03-13 1986-09-18 Hoechst Ag, 6230 Frankfurt NEW 3-PYRIDYLMETHYLNAPHTYL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS
DE3628545A1 (en) * 1985-09-23 1987-04-23 Hoechst Ag ARYLMETHYLAZOLES AND THEIR SALTS, METHOD FOR THE PRODUCTION THEREOF, MEANS CONTAINING THEM AND THEIR USE
AU5285593A (en) * 1992-10-21 1994-05-09 Sankyo Company Limited Azole compound
WO1999028315A1 (en) * 1997-11-28 1999-06-10 Lg Chemical Ltd. Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
JP4546589B2 (en) * 1998-04-23 2010-09-15 武田薬品工業株式会社 Naphthalene derivatives
WO1999054309A1 (en) * 1998-04-23 1999-10-28 Takeda Chemical Industries, Ltd. Naphthalene derivatives, their production and use
FR2796070B1 (en) * 1999-07-06 2003-02-21 Lipha BENZODIAZEPINES DERIVATIVES FOR USE IN THE TREATMENT OF DYSLIPIDEMIA, ATHEROSCLEROSIS AND DIABETES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS OF PREPARATION
JP4520012B2 (en) * 1999-10-22 2010-08-04 武田薬品工業株式会社 1-Substituted-1- (1H-imidazol-4-yl) methanols
PE20010781A1 (en) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd COMPOUNDS 1- (1H-IMIDAZOL-4-IL) -1- (NAFTIL-2-SUBSTITUTED) ETHANOL, ITS PRODUCTION AND USE

Also Published As

Publication number Publication date
AU2004257257A1 (en) 2005-01-27
BRPI0412424A (en) 2006-09-05
RU2363696C2 (en) 2009-08-10
NO20060114L (en) 2006-02-09
IL172812A0 (en) 2006-06-11
JP4832295B2 (en) 2011-12-07
CN1819996A (en) 2006-08-16
IS8223A (en) 2006-01-10
KR20060052799A (en) 2006-05-19
SG144941A1 (en) 2008-08-28
WO2005007631A1 (en) 2005-01-27
JP2007523866A (en) 2007-08-23
CA2532078A1 (en) 2005-01-27
CN1819996B (en) 2010-10-27
AU2004257257B2 (en) 2011-05-12
EP1654236A1 (en) 2006-05-10
MXPA06000401A (en) 2006-03-17
RU2006103996A (en) 2006-07-10

Similar Documents

Publication Publication Date Title
UA87822C2 (en) Naphthylene derivatives as cytochrome p450 inhibitors
IL198979A (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
TW200728307A (en) Novel spirochromanone derivatives
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
NZ598242A (en) Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
WO2008075172A3 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
MY140638A (en) New heterocyclic compounds, which are active as inhibitors of beta-lactamases
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
AU2003297291A1 (en) Substituted arylcyclopropylacetamides as glucokinase activators
BR0316583A (en) Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (parent-1)
MX2007004699A (en) Indole and benzimidazole derivatives.
TW200612958A (en) Substituted imidazole derivatives
WO2007084728A3 (en) 2-imino-benzimidazoles
NO20083708L (en) 4-Phenyl-thiazole-5-carboxylic acid and 4-phenyl-thiazole-5-carboxylmides as PLK1 inhibitors
UA97256C2 (en) Substituted pyrazole and triazole compounds as ksp (kinesin spindle protein) inhibitors
MX2009010302A (en) Indole derivative having cpla2 inhibitory activity, use of the same and method for producing the same.
DK1753723T3 (en) Substituted quinoline derivatives as mitotic kinesin inhibitors
AU2001230395A1 (en) Use of cox-2 inhibitors as gastroprokinetics
GEP20115166B (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
WO2004012663A3 (en) Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
WO2005028474A3 (en) Pyrazoloquinoline derivatives as chk-1 inhibitors
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
AP2002002466A0 (en) 3-heterocycliylpropanohydroxamic acid PCP INHIBITORS.
TW200613289A (en) Prodrugs of hiv protease inhibitors